These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8390969)

  • 21. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
    Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of middle molecules on the anemia of uremic patients.
    Leber HW; Spiegelhalter R; Ulm A; Goubeaud G; Rawer P
    Artif Organs; 1978 Nov; 2(4):378-81. PubMed ID: 743010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of low-molecular uremic toxins on the metabolic systems of human erythrocytes].
    Kopczyński Z
    Pol Tyg Lek; 1982 Mar; 37(1):21-4. PubMed ID: 7111067
    [No Abstract]   [Full Text] [Related]  

  • 24. Technical aspects on middle molecules: separation, isolation, and identification.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():8-12. PubMed ID: 7295100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The red blood cell as a model for the study of uremic toxins.
    Smith EK; Welt LG
    Arch Intern Med; 1970 Nov; 126(5):827-30. PubMed ID: 4248903
    [No Abstract]   [Full Text] [Related]  

  • 26. Separation, identification of uremic middle molecules, and preliminary study on their toxicity.
    Li G; Chu J; Liu X; Yuan Z
    Clin Chim Acta; 2004 Dec; 350(1-2):89-98. PubMed ID: 15530464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium pump and Na+/H+ activities in uremic erythrocytes. A microcalorimetric and pH-metric study.
    Kovacic H; Gallice P; Brunet P; Berland Y; Crevat A
    Clin Chim Acta; 1997 Mar; 259(1-2):31-40. PubMed ID: 9086292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of uremic middle molecules on the activity of erythrocyte lactate dehydrogenase (LDH)].
    Severini G; Malaguti-Aliberti L
    Ann Ist Super Sanita; 1985; 21(3):357-61. PubMed ID: 3834809
    [No Abstract]   [Full Text] [Related]  

  • 29. The synthesis of middle molecular substances in rat tissues: in vitro study.
    Dzúrik R; Cernácek P; Spustová V; Válek A
    Proc Eur Dial Transplant Assoc; 1978; 15():633-5. PubMed ID: 740703
    [No Abstract]   [Full Text] [Related]  

  • 30. Analysis of plasma middle molecular fraction in uremic patients.
    Kovalishin YaF
    Biomater Artif Cells Artif Organs; 1987; 15(3):605-10. PubMed ID: 3440134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Separation and quantification of the "middle molecules" in uremia.
    Chapman GV; Ward RA; Farrell PC
    Kidney Int; 1980 Jan; 17(1):82-8. PubMed ID: 7374022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of blood toxicity in chronic uremia by an improved chromatographic method.
    Politi L; D'Angelo AR; Caramia M; Molinaro M; Nicoletti R; Cerulli N; Moriggi M; Scandurra R
    Clin Exp Dial Apheresis; 1981; 5(3):277-84. PubMed ID: 7333038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uremic middle molecules: analytical study of middle molecular weight fractions subpeak b4-2.
    Le Moel G; Strecker G; Cueille G; Boudet J; Man NK; Galli A; Agneray J
    Artif Organs; 1981; 4 Suppl():17-21. PubMed ID: 7295087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Search for peptidic "middle molecules" in uremic sera: isolation and chemical identification of fibrinogen fragments.
    Kaplan B; Cojocaru M; Unsworth E; Knecht A; Martin BM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Oct; 796(1):141-53. PubMed ID: 14552825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transport of uremic toxins through conventional hemodialysis membranes.
    Jörstad S; Smeby LC; Wideröe TE; Berg KJ
    Clin Nephrol; 1979 Oct; 12(4):168-73. PubMed ID: 509791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitor of insulin binding to erythrocytes in plasma of uremic patients.
    Milutinović S; Breyer D; Janković N; Molnar V; Stefović A; Rocić B
    Nephron; 1983; 34(2):99-103. PubMed ID: 6346120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Studies on the significance of middle molecular retention products as uremia toxins].
    Goubeaud G; Leber HW; Schott HH
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1244-6. PubMed ID: 611827
    [No Abstract]   [Full Text] [Related]  

  • 38. ["Middle molecules" as nonspecific regulators of phagocyte activity].
    Volchegorskiĭ IA; Vlasov AV; Livshits GE; Akhkiamov EM; Skobeleva NA; Lifshits RI; Ebert LIa
    Biull Eksp Biol Med; 1995 Feb; 119(2):159-62. PubMed ID: 7670039
    [No Abstract]   [Full Text] [Related]  

  • 39. The presence of a natriuretic factor in urine of patients with chronic uremia. The absence of the factor in nephrotic uremic patients.
    Bourgoignie JJ; Hwang KH; Ipakchi E; Bricker NS
    J Clin Invest; 1974 Jun; 53(6):1559-67. PubMed ID: 4830222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of transepithelial sodium transport in the frog skin by a low molecular weight fraction of uremic serum.
    Bourgoignie J; Klahr S; Bricker NS
    J Clin Invest; 1971 Feb; 50(2):303-11. PubMed ID: 5540168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.